Immunovia AB

Immunovia AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Immunovia AB has 672.67M shares outstanding.

As of June 30, 2026, Immunovia AB maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.84, indicating elevated leverage, while an interest coverage ratio of -13.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Immunovia AB posted a negative return on equity (ROE) of -426.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -213.15, reflecting losses generated across the asset base. The company generates approximately 10,400.42 in revenue per employee across its workforce of 12.00, a quick read on workforce productivity versus industry peers.

As of the close on September 2, 2026, Immunovia AB's stock has declined approximately 74.28% over the past 52 weeks. The 50-day moving average sits at 3.33, while the 200-day moving average is 1.21.

Over the twelve months ended June 30, 2026, Immunovia AB generated 124,805.06 in revenue and converted that into -9.11M in net income, yielding earnings per share of -0.02. EBITDA reached -8.34M, while operating income came in at -8.53M.

As of June 30, 2026, Immunovia AB holds 3.60M in cash and equivalents against 337,283.09 in total debt, resulting in a net debt position of -3.60M. Total book value stands at 2.44M, with working capital of 1.44M providing operational flexibility.

Immunovia AB produced -7.98M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -573,381.25 in capital expenditures, free cash flow totaled -8.55M - equivalent to -0.02 per share.

Over the twelve months ended June 30, 2026, Immunovia AB posted a gross margin of 56.94, reflecting its pricing power and cost economics. The operating margin of -6,837.93 and net profit margin of -7,300.33 provide insight into operational efficiency.

Immunovia AB's most recent stock split took place on October 2, 2025.